What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
BACKGROUND:It is unclear what to do when people with type 2 diabetes have had no or a limited glycemic response to a recently introduced medication. Intra-individual HbA1c variability can obscure true response. Some guidelines suggest stopping apparently ineffective therapy, but no studies have addr...
Autors principals: | McGovern, A, Dennis, J, Shields, B, Hattersley, A, Pearson, E, Jones, A, Mastermind Consortium |
---|---|
Altres autors: | Farmer, A |
Format: | Journal article |
Idioma: | English |
Publicat: |
BioMed Central
2019
|
Ítems similars
-
What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study
per: Andrew P. McGovern, et al.
Publicat: (2019-04-01) -
Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?
per: Angus G Jones, et al.
Publicat: (2016-01-01) -
Costs and treatment pathways for type 2 diabetes in the UK: a Mastermind Cohort study
per: Eibich, U, et al.
Publicat: (2017) -
Mastermind ophthalmology
per: Madhav
Publicat: (2007-01-01) -
Predicting post one-year durability of glucose-lowering monotherapies in patients with new-onset type 2 diabetes
per: Agbaje, O, et al.
Publicat: (2017)